-
1.发明授权6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use 有权6-芳基氧基 - 或6-芳氧基 - 喹啉-2-甲酰胺及其使用方法公开(公告)号：US09452986B2
公开(公告)日：2016-09-27
申请号：US14613579
申请日：2015-02-04
Applicant: AbbVie Inc.
Inventor： Andrew Bogdan , Marlon D. Cowart , David A. DeGoey , Tammie K. Jinkerson , John R. Koenig , Michael E. Kort , Bo Liu , Mark A. Matulenko , Derek W. Nelson , Meena V. Patel , Hillary Peltier , Marc J. Scanio , Brian D. Wakefield
IPC: C07D215/48 , C07D401/12 , C07D409/14 , C07D487/08 , C07D401/14 , C07D487/04 , C07D405/14 , C07D417/14 , C07D471/04 , C07D405/12 , C07D409/12 , C07D417/12
CPC classification number: C07D215/48 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
-
公开(公告)号：US20130172334A1
公开(公告)日：2013-07-04
申请号：US13716862
申请日：2012-12-17
Applicant: AbbVie Inc.
Inventor： Michael J. Dart , Philip R. Kym , Eric A. Voight , Anurupa Shrestha , Jerome F. Daanen , Tammie K. Jinkerson , Ryan G. Keddy , Sridhar Peddi , Arthur Gomtsyan , Michael E. Kort , Gregory A. Gfesser , Kevin R. Woller , Derek W. Nelson
IPC: C07D405/12 , A61K31/192 , C07D239/80 , C07D413/12 , A61K31/4704 , C07D491/052 , A61K31/517 , A61K31/4709 , A61K31/538 , A61K45/06 , C07D215/38
CPC classification number: C07D405/12 , A61K31/192 , A61K31/4704 , A61K31/4709 , A61K31/517 , A61K31/538 , A61K45/06 , C07D215/227 , C07D215/38 , C07D239/80 , C07D265/36 , C07D413/12 , C07D413/14 , C07D491/052
Abstract: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Abstract translation: 本文公开了式（I）的化合物或其药学上可接受的盐，其中X1，L，Rx，Ry，G，Z，A，m，n和p如说明书中所定义。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
3.发明申请6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE 有权6-异亮氨酸或6-芳基喹啉-2-羧酸酰胺及其使用方法公开(公告)号：US20160355482A1
公开(公告)日：2016-12-08
申请号：US15239554
申请日：2016-08-17
Applicant: AbbVie Inc.
Inventor： Andrew Bogdan , Marlon D. Cowart , David A. DeGoey , Tammie K. Jinkerson , John R. Koenig , Michael E. Kort , Bo Liu , Mark A. Matulenko , Derek W. Nelson , Meena V. Patel , Hillary Peltier , Marc J. Scanio , Brian D. Wakefield
IPC: C07D215/48 , C07D409/14 , C07D487/08 , C07D471/04 , C07D487/04 , C07D405/14 , C07D417/14 , C07D401/12 , C07D401/14
CPC classification number: C07D215/48 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
Abstract translation: 和其药学上可接受的盐，酯，酰胺或放射性标记形式，其中R1，R2和R3如说明书中所定义，可用于治疗由电压门控钠通道（例如Nav1）预防或改善的病症或病症。 7和/或Nav1.8。 公开了制备化合物的方法。 还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。
-
公开(公告)号：US09969693B2
公开(公告)日：2018-05-15
申请号：US15239554
申请日：2016-08-17
Applicant: AbbVie Inc.
Inventor： Andrew Bogdan , Marlon D. Cowart , David A. DeGoey , Tammie K. Jinkerson , John R. Koenig , Michael E. Kort , Bo Liu , Mark A. Matulenko , Derek W. Nelson , Meena V. Patel , Hillary Peltier , Marc J. Scanio , Brian D. Wakefield
IPC: C07D215/48 , C07D401/12 , C07D409/14 , C07D487/08 , C07D401/14 , C07D487/04 , C07D405/14 , C07D417/14 , C07D471/04
CPC classification number: C07D215/48 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav 1.7 and/or Nav 1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
-
Patent Agency Ranking
5.发明申请6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE 有权6-异亮氨酸或6-芳基喹啉-2-羧酸酰胺及其使用方法公开(公告)号：US20150218102A1
公开(公告)日：2015-08-06
申请号：US14613579
申请日：2015-02-04
Applicant: AbbVie Inc.
Inventor： Andrew Bogdan , Marlon D. Cowart , David A. DeGoey , Tammie K. Jinkerson , John R. Koenig , Michael E. Kort , Bo Liu , Mark A. Matulenko , Derek W. Nelson , Meena V. Patel , Hillary Peltier , Marc J. Scanio , Brian D. Wakefield
IPC: C07D215/48 , C07D409/14 , C07D487/08 , C07D471/04 , C07D487/04 , C07D405/14 , C07D417/14 , C07D401/12 , C07D401/14
CPC classification number: C07D215/48 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
Abstract translation: 式（I）化合物及其药学上可接受的盐，酯，酰胺或放射性标记形式，其中R1，R2和R3如本说明书中所定义，可用于治疗由电压门控钠预防或改善的病症或病症 通道，例如Nav1.7和/或Nav1.8。 公开了制备化合物的方法。 还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。
-
公开(公告)号：US08969325B2
公开(公告)日：2015-03-03
申请号：US13716862
申请日：2012-12-17
Applicant: AbbVie Inc.
Inventor： Michael J. Dart , Philip R. Kym , Eric A. Voight , Anurupa Shrestha , Jerome F. Daanen , Tammie K. Jinkerson , Ryan G. Keddy , Sridhar Peddi , Arthur Gomtsyan , Michael E. Kort , Gregory A. Gfesser , Kevin R. Woller , Derek W. Nelson
IPC: C07D405/12 , C07D215/38 , C07D239/80 , C07D413/12 , C07D491/052 , A61K31/192 , A61K31/4704 , A61K31/4709 , A61K31/517 , A61K31/538 , A61K45/06 , C07D413/14 , C07D215/227 , C07D265/36
CPC classification number: C07D405/12 , A61K31/192 , A61K31/4704 , A61K31/4709 , A61K31/517 , A61K31/538 , A61K45/06 , C07D215/227 , C07D215/38 , C07D239/80 , C07D265/36 , C07D413/12 , C07D413/14 , C07D491/052
Abstract: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Abstract translation: 本文公开了式（I）的化合物或其药学上可接受的盐，其中X1，L，Rx，Ry，G，Z，A，m，n和p如说明书中所定义。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
公开(公告)号：US20180334435A1
公开(公告)日：2018-11-22
申请号：US15952682
申请日：2018-04-13
Applicant: AbbVie Inc.
Inventor： Andrew Bogdan , Marlon D. Cowart , David A. DeGoey , Tammie K. Jinkerson , John R. Koenig , Michael E. Kort , Bo Liu , Mark A. Matulenko , Derek W. Nelson , Meena V. Patel , Hillary Peltier , Marc J. Scanio , Brian D. Wakefield
IPC: C07D215/48 , C07D487/04 , C07D405/12 , C07D487/08 , C07D401/12 , C07D471/04 , C07D417/14 , C07D405/14 , C07D409/14 , C07D401/14 , C07D409/12 , C07D417/12
CPC classification number: C07D215/48 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
-
公开(公告)号：US20170226062A9
公开(公告)日：2017-08-10
申请号：US15239554
申请日：2016-08-17
Applicant: AbbVie Inc.
Inventor： Andrew Bogdan , Marlon D. Cowart , David A. DeGoey , Tammie K. Jinkerson , John R. Koenig , Michael E. Kort , Bo Liu , Mark A. Matulenko , Derek W. Nelson , Meena V. Patel , Hillary Peltier , Marc J. Scanio , Brian D. Wakefield
IPC: C07D215/48 , C07D409/14 , C07D487/08 , C07D471/04 , C07D487/04 , C07D405/14 , C07D417/14 , C07D401/12 , C07D401/14
CPC classification number: C07D215/48 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
-
9.发明申请公开(公告)号：US20150231141A1
公开(公告)日：2015-08-20
申请号：US14628131
申请日：2015-02-20
Applicant: AbbVie Inc.
Inventor： Alan S. Florjancic , Michael J. Dart , Keith B. Ryther , Arturo Perez-Medrano , William A. Carroll , Meena V. Patel , Karin Rosemarie Tietje , Tongmei Li , Teodozyj Kolasa , Megan E. Gallagher , Sridhar Peddi , Jennifer M. Frost , Derek W. Nelson
IPC: A61K31/5377 , A61K31/4439 , A61K31/428 , A61K31/427 , A61K31/506 , A61K31/426 , A61K31/4709
CPC classification number: A61K31/429 , C07D277/46 , C07D277/48 , C07D277/82 , C07D417/04 , C07D417/06 , C07D417/12 , C07D493/08 , C07D513/04
Abstract: The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and L2, are defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，前药，前体药物或其组合的盐，其中R1，R2，R3，R4和L2在说明书中定义，包含这些化合物的组合物， 以及使用这些化合物和组合物治疗病症和病症的方法。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.052 seconds)
